EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access

TREM2 and LAG-3 in cancer and Alzheimer’s disease immunotherapy

Shaoren Yuan, Natalie S Fuchs, Somaya A Abdel-Rahman, Baljit Kaur, Moustafa T Gabr

Trends in Pharmacological Sciences · 2025

DOI: 10.1016/j.tips.2025.06.010 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Trends in Pharmacological Sciences, 2025. Verfasst von Shaoren Yuan und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiology, Molecular Imaging Innovations Institute (MI3), Weill Cornell Medicine, New York, NY 10065, USA. Hauptthemen laut MEDLINE: Lymphocyte Activation Gene 3 Protein, Receptors, Immunologic, Alzheimer Disease, Neoplasms. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 83 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIA NIH HHS, National Institute on Aging.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Alzheimer's disease (AD) and cancer are immune-mediated disorders characterized by chronic neuroinflammation and immune evasion, respectively. Recent studies implicate two key immune regulators in both diseases: LAG-3, an adaptive immune checkpoint receptor, and TREM2, an innate receptor expressed on microglia and tumor-associated macrophages (TAMs). LAG-3 inhibitors have demonstrated clinical efficacy in cancer and are being explored in AD research. TREM2 activation supports microglial function in AD, while its inhibition may counteract immunosuppressive macrophages in cancer. In this review we compare the roles, mechanisms, and therapeutic strategies targeting LAG-3 and TREM2 in both diseases. We highlight their distinct immune compartmentalization and the importance of context-specific modulation. Strategies include LAG-3 blockade in cancer and AD, and TREM2 agonism or antagonism depending on disease context. We discuss a framework integrating immune compartment, disease state, and therapeutic modality to guide cross-domain immunotherapy development in cancer and AD.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lymphocyte Activation Gene 3 ProteinReceptors, ImmunologicAlzheimer DiseaseNeoplasmsImmunotherapyHumansMicrogliaTumor-Associated MacrophagesAnimalsMembrane Glycoproteins

Stichwörter der Autor:innen

TREM2drug discoveryimmune checkpoint inhibitorsimmunotherapymicroglia

Substanzen

Lymphocyte Activation Gene 3 ProteinTREM2 protein, humanReceptors, ImmunologicLag3 protein, humanMembrane Glycoproteins

Autor:innen und Institutionen

  • Department of Radiology, Molecular Imaging Innovations Institute (MI3), Weill Cornell Medicine, New York, NY 10065, USA.
  • Department of Radiology, Molecular Imaging Innovations Institute (MI3), Weill Cornell Medicine, New York, NY 10065, USA. Electronic address: mog4005@med.cornell.edu.

Förderung

  • NIA NIH HHS
  • National Institute on Aging

Zitieren

APA

Yuan, S., Fuchs, N. S., Abdel-Rahman, S. A., Kaur, B., & Gabr, M. T. (2025). TREM2 and LAG-3 in cancer and Alzheimer’s disease immunotherapy. Trends in Pharmacological Sciences. https://doi.org/10.1016/j.tips.2025.06.010

Vancouver

Yuan S, Fuchs NS, Abdel-Rahman SA, Kaur B, Gabr MT. TREM2 and LAG-3 in cancer and Alzheimer’s disease immunotherapy. Trends in Pharmacological Sciences. 2025. doi:10.1016/j.tips.2025.06.010

BibTeX
@article{Yuan2025,
  author = {Yuan, Shaoren and Fuchs, Natalie S and Abdel-Rahman, Somaya A and Kaur, Baljit and Gabr, Moustafa T},
  title = {TREM2 and LAG-3 in cancer and Alzheimer’s disease immunotherapy},
  journal = {Trends in Pharmacological Sciences},
  year = {2025},
  doi = {10.1016/j.tips.2025.06.010}
}
Kostenlos starten →